Your browser is no longer supported. Please, upgrade your browser.
CELG Celgene Corporation monthly Stock Chart
CELG [NASD]
Celgene Corporation
IndexS&P 500 P/E49.63 EPS (ttm)2.49 Insider Own0.20% Shs Outstand777.97M Perf Week-1.90%
Market Cap95.99B Forward P/E14.08 EPS next Y8.77 Insider Trans32.23% Shs Float775.96M Perf Month3.28%
Income2.00B PEG2.23 EPS next Q1.64 Inst Own79.90% Short Float1.02% Perf Quarter6.50%
Sales11.23B P/S8.55 EPS this Y28.10% Inst Trans1.47% Short Ratio1.92 Perf Half Y11.59%
Book/sh8.49 P/B14.53 EPS next Y21.33% ROA7.40% Target Price140.13 Perf Year22.72%
Cash/sh10.24 P/C12.04 EPS next 5Y22.28% ROE35.00% 52W Range94.42 - 127.64 Perf YTD6.59%
Dividend- P/FCF25.66 EPS past 5Y11.80% ROI11.70% 52W High-3.34% Beta1.78
Dividend %- Quick Ratio3.50 Sales past 5Y18.30% Gross Margin96.10% 52W Low30.67% ATR2.31
Employees7132 Current Ratio3.70 Sales Q/Q16.30% Oper. Margin25.00% RSI (14)53.38 Volatility1.73% 1.87%
OptionableYes Debt/Eq2.17 EPS Q/Q-22.20% Profit Margin17.80% Rel Volume0.69 Prev Close123.22
ShortableYes LT Debt/Eq2.09 EarningsApr 27 BMO Payout0.00% Avg Volume4.12M Price123.38
Recom1.80 SMA20-0.35% SMA503.54% SMA20010.58% Volume2,845,293 Change0.13%
Mar-09-17Initiated UBS Buy $140
Nov-09-16Downgrade Standpoint Research Buy → Hold
Nov-08-16Initiated Mizuho Buy $130
Jul-15-16Initiated Stifel Buy $138
Apr-29-16Reiterated Sun Trust Rbsn Humphrey Buy $145 → $147
Feb-25-16Initiated Citigroup Buy $130
Jan-20-16Initiated Credit Suisse Outperform
Jan-14-16Initiated Standpoint Research Buy $130
Jan-08-16Initiated Sun Trust Rbsn Humphrey Buy $145
Jan-07-16Initiated Sun Trust Rbsn Humphrey Buy
Nov-06-15Reiterated UBS Buy $156 → $145
Oct-01-15Upgrade JP Morgan Neutral → Overweight
Sep-09-15Initiated Jefferies Buy
Sep-01-15Initiated Raymond James Strong Buy $160
Jul-24-15Reiterated UBS Buy $142 → $156
Jul-24-15Reiterated JMP Securities Mkt Outperform $133 → $147
Jul-24-15Reiterated Cantor Fitzgerald Buy $146 → $163
Jul-21-15Reiterated Piper Jaffray Overweight $144 → $160
Jul-15-15Reiterated RBC Capital Mkts Outperform $135 → $150
Jul-15-15Reiterated Barclays Equal Weight $120 → $130
Mar-24-17 01:13PM  2 Asset Classes That Are Arguably Still Cheap at Motley Fool
Mar-22-17 09:30AM  Zacks Investment Ideas feature highlights: Nasdaq Biotechnology Index, Gilead, Valeant Pharma, Celgene and Amgen
07:37AM  A Look at Ionis Pharmaceuticals Spinraza
Mar-21-17 05:52PM  3 Value Stocks Senior Citizens Could Buy Right Now at Motley Fool
Mar-20-17 10:06AM  Why Biotech Stock Gilead (GILD) Could Be a Value Trap
09:50AM  Jefferies Has 4 Red-Hot Biotech and Pharmaceutical Stocks to Buy Now
09:17AM  Leerink Presents: Your 2017 Biopharma Catalyst Tracker
08:42AM  4 Stocks at 52-Week Highs That Are Still Worth Buying Today at Motley Fool
Mar-17-17 08:43AM  Celgene Corp. :CELG-US: Earnings Analysis: Q4, 2016 By the Numbers : March 17, 2017
Mar-16-17 07:08AM  [$$] Celgene Shows Savvy as Gilead Keeps Backsliding at Barrons.com
Mar-15-17 04:43PM  5 Things You Probably Didn't Know About Celgene Corporation at Motley Fool
04:29PM  Top Biotech Hits Buy Point As CEO Cites 'Momentum' In Key Drivers
Mar-14-17 11:08AM  Credit Suisse's Top 10 Stocks for 2017
10:35AM  Amgen's Repatha Meets Primary Endpoint in Phase III Study
Mar-12-17 02:57PM  Top Biotech May 'Unveil' Breakthrough Treatment And Breakout Move
Mar-10-17 04:41PM  Top Stocks Billionaires Are Buying Now at Motley Fool
04:39PM  Under-The-Radar Biotech Tests Buy Zone; Cancer Trial Results 'Encouraging'
11:30AM  Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus
10:30AM  Major Biotechs See a Retreat in Short Interest
09:03AM  The 3 Drugs Powering Celgene to the Top of Your Portfolio at Motley Fool
Mar-09-17 06:32PM  Top Research Reports for March 9, 2017
04:03PM  Will Pfizer Take On Celgene, Other Rivals With Leukemia Drug?
01:57PM  Celgene's Deep Pipeline Can Reassure Investors
01:40PM  Drugs, travel, jewelry and social media in the blitz
10:00AM  Coverage initiated on Celgene by UBS
09:03AM  5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade at Motley Fool
Mar-08-17 05:17PM  Valeant (VRX) Issues Notes, Restructures Debt; Shares Down
04:55PM  Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug
09:45AM  Ionis Pharma Lipid Disorder Candidate Positive in Phase III
09:32AM  3 Safe Stocks You Can Buy Right Now at Motley Fool
08:18AM  Biotech Stock Roundup: Trump Tweet Hits Biotech Stocks, Concert Gains on Vertex Deal
Mar-07-17 04:08PM  GlaxoSmithKline's Nucala Positive in Label Expansion Study
03:58PM  Biotech beat up?
03:04PM  3 Biotech Stocks You Don't Have to Babysit at Motley Fool
09:48AM  Trump's Latest Drug Pricing Tweet Hits Biotech Stocks at The Wall Street Journal
08:04AM  Here's Why the Best Is Yet to Come for Gilead Sciences, Inc. at Motley Fool
Mar-06-17 10:20AM  Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy
08:41AM  J&J Presents Positive Phase III Data on Psoriasis Candidate
Mar-05-17 12:35PM  Celgene Announces Oral OTEZLA Demonstrated Significant Improvement vs Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy
08:55AM  Oral OTEZLA® (Apremilast) Demonstrated Significant Improvement versus Placebo in Trial of Patients with Moderate Plaque Psoriasis Who Were Naïve to Systemic and Biologic Therapy Business Wire
Mar-04-17 10:52AM  How to Profit from Celgene (CELG) Options
06:42AM  Bad News Biotechs: What's Next for Juno and PTC Therapeutics? at Motley Fool
Mar-03-17 07:00PM  A Remarkable Approach to Profit from Celgene Options
09:32AM  Nektar Therapeutics (NKTR) Loss Wider than Expected in Q4
07:00AM  Celgene to Present New Data from Clinical Trials on Oral OTEZLA® (apremilast) at American Academy of Dermatology Congress Business Wire
Mar-02-17 07:37PM  Why Juno Therapeutics Inc. Tanked on Thursday at Motley Fool
05:08PM  Merrimack (MACK) Q4 Loss Lower than Expected, Revenues Top
03:21PM  Why Celgene's Shares Rallied Higher in February at Motley Fool
09:57AM  Geron (GERN) Q4 Loss Narrows; Focus Remains on Imetelstat
09:50AM  Billionaire George Soros Bought These 2 Biotech Stocks at Motley Fool
09:30AM  Zacks Industry Outlook Highlights: GlaxoSmithKline, Celgene and Exelixis
Mar-01-17 06:03PM  Juno Therapeutics' Q4 Financial Results Overshadowed by Pipeline Setback at Motley Fool
05:09PM  Juno ends development of high-profile leukemia drug after deaths
03:19PM  M&As, Pipeline Catalysts to Drive Pharma Sector
03:15PM  Agios CEO touts path from 'a blank piece of paper' to cusp of drug approval at bizjournals.com
10:37AM  Regeneron Could See a Modest Rise in Net Profit Margins in 2017
10:04AM  [$$] Cancer Test Makers Raise Nearly $1 Billion at The Wall Street Journal
09:37AM  Medicines Company (MDCO) Q4 Loss Narrower than Expected
08:36AM  Why Is Celgene (CELG) Up 6% Since the Last Earnings Report?
08:06AM  Carl Icahn Takes Aim at Bristol-Myers Squibb at Motley Fool
07:30AM  FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation Business Wire
07:24AM  Biotech Stock Roundup: Kite Soars on CAR-T Data, EXEL in Immuno-Oncology Deals
Feb-28-17 05:54PM  Why Gileads Valuation Is Low Compared to Peers
12:17PM  Endo (ENDP) Beats on Q4 Earnings, Revenues; Guides Low
12:15PM  Horizon (HZNP) Misses on Earnings in Q4, View Disappoints
10:15AM  Short Sellers Hike Their Bets in Major Biotechs
09:27AM  Smart Investors Are Already Buying These Stocks for Retirement at Motley Fool
09:24AM  Perrigo to Sell Tysabri Royalties; Issues Tepid 2017 View
Feb-27-17 08:23AM  Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss
07:37AM  Why Vertex Expects Its Profit Margin to Rise in 2017
07:30AM  Celgene Corporation to Webcast at Upcoming Investor Conferences Business Wire
Feb-24-17 03:25PM  Emergent (EBS) Beats Earnings, Revenue Estimates in Q4
01:45PM  Is There More Than Meets the Eye on Celgenes President, COO Retirement?
10:57AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
05:43AM  REVLIMID® (Lenalidomide) Approved by the European Commission as Monotherapy for the Maintenance Treatment of Patients with Newly Diagnosed Multiple Myeloma after Autologous Stem Cell Transplantation Business Wire
Feb-23-17 05:36PM  CELGENE CORP /DE/ Files SEC form 8-K, Change in Directors or Principal Officers
04:30PM  Celgene Announces Retirement of President and Chief Operating Officer, Jacqualyn Fouse, Ph.D. and Promotion of Scott Smith to President and Chief Operating Officer Business Wire
02:20PM  Celgenes Revlimid Secures Label Expansion at Investopedia
08:02AM  Here's Why Celgene's Latest Drug Is So Exciting at Motley Fool
Feb-22-17 04:02PM  FDA Expands Indication for REVLIMID® (lenalidomide) as a Maintenance Treatment for Patients with Multiple Myeloma Following Autologous Hematopoietic Stem Cell Transplant (auto-HSCT) Business Wire
06:43AM  Biotech Stock Roundup: Alexion Reports 4Q Results, Celgene MS Drug Looks Promising
Feb-21-17 07:01PM  3 Great Stocks to Buy Instead of NVIDIA Corporation at Motley Fool
08:15AM  Blog Coverage Celgene's Multiple Sclerosis Drug Reported Positive Phase-III Results Accesswire
06:00AM  [$$] US exporters line up behind tax code overhaul at Financial Times
Feb-20-17 10:30AM  Celgene MS Drug Reports Positive Phase 3 Data at Investopedia
08:24AM  3 Top Drug Stocks That Can Be Purchased on the Cheap This Winter at Motley Fool
07:52AM  Forget Alexion, Buy these 4 Biotech Stocks Instead
Feb-19-17 11:41AM  Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands? at Motley Fool
Feb-17-17 04:15PM  Celgene MS Drug Wins In Trial; Will Safety Top Novartis, Biogen?
01:30PM  Stocks Quietly Mixed In Afternoon; Skyworks Breaks Out, Celgene Bases
08:39AM  Celgene Multiple Sclerosis Pill Succeeds in First Late-Stage Clinical Trial
08:14AM  CELGENE CORP /DE/ Files SEC form 8-K, Other Events
07:30AM  Celgene Announces Positive Results from Phase III SUNBEAM Trial of Oral Ozanimod in Patients with Relapsing Multiple Sclerosis Business Wire
Feb-16-17 02:39PM  3 Biotechs With Tremendously Promising Pipelines at Motley Fool
08:53AM  Agios (AGIO) Q4 Loss Narrower than Expected; Revenues Up Y/Y
Feb-15-17 06:35PM  Cramer fires back at naysayers: Here's your proof that th...
06:22PM  Cramer fires back at naysayers: Here's your proof that this rally is real at CNBC
05:59PM  Proof the rally is real
01:04PM  CELGENE CORP /DE/ Financials
10:56AM  Celgene Could Have One More Powerful Move Higher
Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; AG-881 for glioma with IDH mutations; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; and durvalumab, an anti-PDL-1 antibody, for multiple hematological cancers. The company has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc.; The company was founded in 1980 and is headquartered in Summit, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KAPLAN GILLADirectorMar 03Option Exercise25.587,500191,81387,142Mar 07 04:37 PM
VESSEY RUPERTSee remarksMar 01Sale124.424,000497,672778Mar 02 04:04 PM
CASEY MICHAEL DDirectorFeb 27Option Exercise25.587,500191,8507,500Mar 01 04:15 PM
CASEY MICHAEL DDirectorFeb 27Sale121.557,500911,6250Mar 01 04:15 PM
VESSEY RUPERTSee remarksFeb 02Option Exercise0.005,62306,773Feb 06 04:14 PM
Celgene Switzerland LLC10% OwnerFeb 01Buy16.00625,00010,000,0003,456,463Feb 01 04:18 PM
HUGIN ROBERT Jsee remarksJan 05Option Exercise27.4322,708622,767913,909Jan 09 04:11 PM
Smith Scott AndrewSee RemarksDec 23Option Exercise0.006,400039,875Dec 27 04:17 PM
PEHL MICHAEL F.See remarksDec 02Option Exercise0.001,88001,880Dec 06 04:05 PM
Smith Scott AndrewSee RemarksDec 02Option Exercise0.003,750035,419Dec 06 04:05 PM
FOUSE JACQUALYN Asee remarksDec 02Option Exercise0.005,000084,392Dec 06 04:04 PM
Alles Mark JSee RemarksDec 02Option Exercise0.006,5600166,134Dec 06 04:03 PM
VESSEY RUPERTSee remarksNov 22Sale123.182,500307,9501,150Nov 30 04:15 PM
PEHL MICHAEL F.See remarksNov 10Option Exercise68.3920,4241,396,77022,052Nov 15 04:22 PM
PEHL MICHAEL F.See remarksNov 10Sale121.0422,0522,669,1490Nov 15 04:22 PM
Friedman Michael ADirectorNov 09Option Exercise31.8018,600591,48018,600Nov 10 04:14 PM
Friedman Michael ADirectorNov 09Sale116.1018,6002,159,4600Nov 10 04:14 PM
HUGIN ROBERT Jsee remarksNov 09Sale120.00100,00012,000,000922,201Nov 14 05:47 PM
CELGENE CORP /DE/10% OwnerOct 24Buy14.00800,15011,202,1004,834,980Oct 26 04:15 PM
CASEY MICHAEL DDirectorOct 18Option Exercise100.067,500750,45092,985Oct 19 04:16 PM
Friedman Michael ADirectorOct 03Option Exercise29.8656,1161,675,36456,116Oct 05 04:09 PM
Friedman Michael ADirectorOct 03Sale103.6656,1165,816,9850Oct 05 04:09 PM
BARKER RICHARD WDirectorSep 23Option Exercise36.9220,000738,40031,332Sep 26 04:08 PM
BARKER RICHARD WDirectorSep 23Sale110.8220,0002,216,40011,332Sep 26 04:08 PM
MARIO ERNESTDirectorSep 23Sale109.4215,0001,641,30090,058Sep 26 04:08 PM
KAPLAN GILLADirectorSep 19Option Exercise29.267,500219,45079,642Sep 20 04:42 PM
KAPLAN GILLADirectorSep 15Sale106.449,7101,033,53272,142Sep 16 04:15 PM
LOUGHLIN JAMES JDirectorAug 23Option Exercise26.3627,500724,85050,419Aug 24 04:28 PM
LOUGHLIN JAMES JDirectorAug 23Sale114.1027,5003,137,75022,919Aug 24 04:28 PM
CASEY MICHAEL DDirectorAug 22Sale114.0143,1344,917,70785,485Aug 23 04:29 PM
HUGIN ROBERT Jsee remarksJul 28Sale110.00100,00011,000,0001,022,201Aug 01 05:04 PM
MARIO ERNESTDirectorJul 01Option Exercise0.007330105,058Jul 05 04:32 PM
LOUGHLIN JAMES JDirectorJul 01Option Exercise0.00733022,919Jul 05 04:30 PM
Friedman Michael ADirectorJul 01Option Exercise0.0073300Jul 05 04:27 PM
KAPLAN GILLADirectorJul 01Option Exercise0.00733081,852Jul 05 04:28 PM
COX CARRIE SMITHDirectorJul 01Option Exercise0.00733023,146Jul 05 04:27 PM
BARKER RICHARD WDirectorJul 01Option Exercise0.00733011,551Jul 05 04:25 PM
CASEY MICHAEL DDirectorJul 01Option Exercise0.0073300Jul 05 04:26 PM
HUGIN ROBERT Jsee remarksJun 20Sale100.1675,0007,512,0001,122,201Jun 22 04:42 PM
KAPLAN GILLADirectorJun 17Option Exercise0.00333081,119Jun 17 04:18 PM
CASEY MICHAEL DDirectorJun 17Option Exercise0.0033300Jun 17 04:13 PM
Friedman Michael ADirectorJun 17Option Exercise0.0033300Jun 17 04:14 PM
MARIO ERNESTDirectorJun 16Option Exercise0.002,0550113,892Jun 16 06:57 PM
COX CARRIE SMITHDirectorJun 16Option Exercise0.006,200022,413Jun 17 04:14 PM
KAPLAN GILLADirectorJun 15Option Exercise0.006,200080,786Jun 17 04:18 PM
LOUGHLIN JAMES JDirectorJun 12Option Exercise0.002,068021,853Jun 13 05:10 PM
MARIO ERNESTDirectorJun 12Option Exercise0.002,0680103,992Jun 13 05:10 PM
KAPLAN GILLADirectorJun 12Option Exercise0.002,068074,586Jun 13 05:09 PM
BARKER RICHARD WDirectorJun 12Option Exercise0.002,068011,439Jun 13 05:08 PM
CASEY MICHAEL DDirectorJun 12Option Exercise0.002,06800Jun 13 05:08 PM
Friedman Michael ADirectorJun 12Option Exercise0.002,06800Jun 13 05:09 PM
Alles Mark JSee RemarksApr 29Option Exercise0.0011,0000164,636May 03 04:30 PM
HUGIN ROBERT Jsee remarksApr 29Option Exercise0.0060,00001,228,311May 03 04:19 PM
Smith Scott AndrewSee RemarksApr 29Option Exercise0.0010,000036,656May 03 09:28 PM
MARIO ERNESTDirectorApr 26Option Exercise31.805,000158,975101,924Apr 28 04:09 PM
KAPLAN GILLADirectorApr 04Sale101.8415,9671,626,07972,518Apr 05 04:15 PM